Market Research Logo

Global Hemophilia B Market 2015-2019 - Industry Analysis

About hemophilia B

Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

Technavio's analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

Technavio's report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Baxter
  • Grifols
  • Novo Nordisk
  • Pfizer
Other prominent vendors
  • Alnylam
  • Amarna
  • Asklepios
  • Biogen
  • Catalyst Biosciences
  • CSL Behring
  • Dimension Therapeutics
  • Dong-A Scio
  • Emergent BioSolutions
Key market driver
  • Prophylactic treatment
  • For a full, detailed list, view our report
Key market challenge
  • High cost of therapy
  • For a full, detailed list, view our report
Key market trend
  • New technological advancements
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hemophilia B Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Hemophilia B Market: Baxter, Grifols, Novo Nordisk and Pfizer

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, and uniQure.

Commenting on the report, an analyst from Technavio’s team said: “Major vendors are entering into strategic alliances for drug development. Strategic alliances, in terms of licensing and collaboration, help vendors co-develop and commercialize drugs in different regions.”

According to the report, prophylactic treatment is fast gaining popularity among physicians and patients. The treatment increases patients' quality of life in terms of physical strength. It also maintains optimum levels of clotting factors, prevent spontaneous bleeding in individuals with hemophilia B, and reduce joint damage and pains.

Further, the report states that the high cost of treatment leads to the discontinuation of therapy by patients, thereby hampering market growth.

Companies Mentioned

Baxter, Grifols, Novo Nordisk and Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, uniQure.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global hemophilia B market 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Disease overview
    • Understanding the disease
    • Epidemiology
      • Table Global cases of hemophilia B 2010-2013
      • Table Cases of Hemophilia B by region 2012
      • Table Cases of hemophilia B by region 2013
  • Pipeline portfolio
    • Key information of few pipeline candidates
  • Market segmentation by disease severity
    • Table Global hemophilia B market segmentation by disease severity
    • Table Global hemophilia B market segmentation by disease severity 2014
    • Mild hemophilia B
    • Moderate hemophilia B
    • Severe hemophilia B
      • Table Treatment of severe hemophilia B 2014
  • Market segmentation by disease management
    • Table Global hemophilia B market segmentation by disease management
    • On-demand therapy
    • Prophylactic therapy
      • Table Share of prophylactic therapy by region 2014
      • Table Types of prophylaxis
    • Inhibitor therapy
      • Table Global hemophilia B market segmentation by disease management 2014
  • Geographical segmentation
    • Table Global hemophilia B market segmentation 2014
    • Table Global hemophilia B market segmentation by revenue 2014 ($ billions)
  • Market drivers
    • Focus on prophylactic treatment
    • Drugs with prolonged action
    • Patient assistance programs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High cost of therapy
    • Low diagnosis rate in developing countries
    • Complications of available therapies
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Advances in technology
    • Strategic alliances
    • Development of gene therapy products
  • Vendor landscape
    • Competitive scenario
    • Mergers and acquisitions
    • Market share analysis 2014
      • Table Baxter: Global sales of hemophilia B drugs 2014-2017 ($ millions)
      • Table Baxter: Key takeaways
      • Table Grifols: Key takeaways
      • Table Novo Nordisk: Global sales of NovoSeven 2011-2014 ($ millions)
      • Table Novo Nordisk: Key takeaways
      • Table Pfizer: Global sales of BeneFIX 2011-2014 ($ millions)
      • Table Pfizer: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Baxter
    • Grifols
    • Novo Nordisk
      • Table Novo Nordisk: Business segmentation by revenue 2014
      • Table Novo Nordisk: Business segmentation by revenue 2013 and 2014
      • Table Novo Nordisk: Geographical segmentation by revenue 2014
      • Table Novo Nordisk: R&D expenditure 2014
    • Pfizer
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report